Disease description 17

Disease description 18

Epidemiology 19

Disease description 22

Epidemiology 24

Disease description 27

Epidemiology 28

Disease description 31

Epidemiology 33

Disease description 36

Epidemiology 38

Disease description 40

Epidemiology 42

Disease description 45

Epidemiology 46

Disease description 48

Epidemiology 49

Disease description 52

Epidemiology 53

Introduction 78

Analysis of the top 10 cytostatic hormonal therapies 81

Regional dynamics 84

Market analysis by drug class 85

LHRH agonists 85

Anti-androgens 88

Anti-estrogens 91

Aromatase inhibitors 92

Cytostatic hormone therapies sales forecasts 95

Introduction 95

Analysis of top 10 antineoplastic therapies 99

Regional dynamics 101

Market analysis by drug class 102

Anti-metabolites 102

Alkylating agents 106

Other antineoplastics 109

Antineoplastics sales forecasts 117

Introduction 117

Analysis of the top 10 immunostimulants 120

Regional dynamics 123

Market analysis by drug class 124

Interferons 124

Others 127

Immunostimulants sales forecasts 128

Introduction 129

Analysis of top immunosuppressants 130

Regional dynamics 134

Market analysis 135

Overview 135

Leading brand dynamics 136

Immunosuppressives sales forecasts 139

Marketed products 147

R&D compounds 148

Cancer portfolio sales forecasts 149

Marketed products 150

R&D compounds 151

Cancer portfolio sales forecasts 152

Marketed products 153

R&D compounds 154

Cancer portfolio sales forecasts 155

Marketed products 156

R&D compounds 157

Cancer portfolio sales forecasts 158

Marketed products 159

R&D compounds 160

Marketed products 161

R&D compounds 162

Cancer portfolio sales forecasts 163

Marketed products 164

R&D compounds 165

Cancer portfolio sales forecasts 166

Marketed products 167

R&D compounds 168

Cancer portfolio sales forecasts 169

List of Figures

Figure 2.1: External analysis of the Eastern European region 64

Figure 3.2: Competitive dynamics of drug classes within the Eastern European market, 2004 73

Figure 3.3: Competitive dynamics of leading brands in the Eastern European cancer market, 2004 76

Figure 3.4: Competitive dynamics of drug classes within the Eastern European cytostatic hormonal therapies market, 2004 80

Figure 3.5: Competitive dynamics of leading cytostatic hormonal brands in the Eastern European cancer market, 2004 83

Figure 3.6: Competitive dynamics of drug classes within the Eastern European antineoplastics market, 2004 98

Figure 3.7: Competitive dynamics of leading antineoplastic brands in the Eastern European cancer market, 2003–04 100

Figure 3.8: Competitive dynamics of drug classes within the Eastern European immunostimulants market, 2004 120

Figure 3.9: Competitive dynamics of leading immunostimulant brands in the Eastern European cancer market, 2004 122

Figure 3.10: Market share of the leading immunosuppressive agents, 2004 133

Figure 4.11: Key players in the Eastern European cancer market, 2000 & 2004 146

List of Tables

Table 1.1: Estimated epidemiology of prostate cancer across the twelve Eastern European markets, 2004 20

Table 1.2: Forecast epidemiology of prostate cancer forecasts across the twelve Eastern European markets, 2005-10 21

Table 1.3: Estimated epidemiology of lung cancer across the twelve Eastern European markets, 2004 24

Table 1.4: Forecast epidemiology of lung cancer forecasts across the twelve Eastern European markets, 2005-10 26

Table 1.5: Estimated epidemiology of breast cancer across the twelve Eastern European pharmaceutical markets, 2004 29

Table 1.6: Forecast epidemiology of breast cancer across the twelve Eastern European markets, 2005-10 30

Table 1.7: Epidemiology of colorectal cancer across the twelve Eastern European markets, 2004 33

Table 1.8: Forecast epidemiology of colorectal cancer across the twelve Eastern European, 2005-10 35

Table 1.9: Estimated epidemiology of ovarian cancer across the twelve Eastern European markets, 2004 38

Table 1.10: Forecast epidemiology of ovarian cancer across the twelve Eastern European markets, 2005-10 39

Table 1.11: Estimated epidemiology of leukemia across the twelve Eastern European markets, 2004 42

Table 1.12: Forecast epidemiology of leukemia across the twelve Eastern European markets, 2005-10 44

Table 1.13: Estimated prevalence of pancreatic cancer across the twelve Easter European markets, 2004 46

Table 1.14: Forecast prevalence of pancreatic cancer across the twelve Eastern European markets, 2005-10 47

Table 1.15: Estimated epidemiology of lymphoma across the twelve Eastern European markets, 2004 50

Table 1.16: Forecast epidemiology of lymphoma across the twelve Eastern European markets, 2005-10 51

Table 1.17: Estimated epidemiology of uterine cancer across the twelve Eastern European pharmaceutical markets, 2004 53

Table 1.18: Forecast epidemiology of uterine cancer across the twelve Eastern European markets,2005-10 54

Table 2.19: Recent statistics on healthcare sector in twelve Eastern European markets, 2002 60

Table 2.20: Public and private financing in twelve Eastern European markets, 2002 61

Table 2.21: Sales of types of cancer brands in the Eastern European pharmaceutical market, 2000-04 65

Table 2.22: Sales of types of cancer brands in twelve Eastern European markets, 2004 67

Table 3.23: Breakdown of Eastern European cancer market by drug class, 2000–2004 71

Table 3.24: Top 10 cancer products in the Eastern European market, 2004 74

Table 3.25: Cancer sales across Eastern European markets, 2004 77

Table 3.26: Breakdown of Eastern European cytostatic hormonal therapies market by drug class, 2000–04 79

Table 3.27: Leading cytostatic hormonal therapy products in the Eastern European market, 2003–04 81

Table 3.28: Market share of cytostatic hormonal therapies in the Eastern European market, 2004 84

Table 3.29: Sales forecasts for cytostatic hormonal therapy drug classes in the Eastern European market, 2004–10 95

Table 3.30: Breakdown of the Eastern European antineoplastics market by drug class, 2000–04 96

Table 3.31: Leading antineoplastic therapies in the Eastern European market, 2003–04 99

Table 3.32: Market share of antineoplastic therapies in the Eastern European market, 2004 101

Table 3.33: Sales forecasts for antineoplastic drug classes in the Eastern European market, 2004–10 117

Table 3.34: Breakdown of the Eastern European immunostimulants market by drug class, 2000–04 118

Table 3.35: Leading immunostimulant brands in the Eastern European market, 2003–04 121

Table 3.36: Market share of immunostimulating agents in the Eastern European market, 2004 123

Table 3.37: Sales forecasts for immunostimulating agent drug classes in the Eastern European market, 2004–10 128

Table 3.38: Breakdown of the Eastern European immunosuppressive agents market by drug class, 2000–04 130

Table 3.39: Sales of the leading immunosuppressive brands products across the Eastern European market, 2003–04 131

Table 3.40: Market share of immunosuppressive agents in the Eastern European market, 2004 134

Table 3.41: Sales forecasts for immunosuppressive agents in the Eastern European market, 2004–10 139

Table 4.42: Key players in the Eastern European cancer market, 2000–2004 144

Table 4.43: Roche’s marketed Eastern European cancer portfolio, 2004 147

Table 4.44: Roche’s oncology R&D pipeline, 2005 148

Table 4.45: Forecast sales for Roche’s Eastern European cancer portfolio, 2004–10 149

Table 4.46: Novartis’ marketed Eastern European cancer portfolio, 2004 150

Table 4.47: Novartis’ cancer R&D pipeline, 2005 151

Table 4.48: Forecast sales for Novartis’ Eastern European cancer portfolio, 2004–10 152

Table 4.49: AstraZeneca’s marketed Eastern European cancer portfolio, 2004 153

Table 4.50: AstraZeneca’s cancer R&D pipeline, 2005 154

Table 4.51: Forecast sales for AstraZeneca’s Eastern European cancer portfolio, 2004–10 155

Table 4.52: BMS’ marketed Eastern European cancer portfolio, 2004 156

Table 4.53: BMS’ cancer R&D pipeline, 2005 157

Table 4.54: Forecast sales for Bristol Myers Squibb’s Eastern European cancer portfolio, 2004–10 158

Table 4.55: Schering-Plough’s marketed Eastern European cancer portfolio, 2004 159

Table 4.56: Schering-Plough’s cancer R&D pipeline, 2005 160

Table 4.57: Forecast sales for Schering-Plough’s cancer portfolio, 2004–10 161

Table 4.58: Pfizer’s marketed Eastern European cancer portfolio, 2004 162

Table 4.59: Pfizer’s cancer R&D pipeline, 2005 163

Table 4.60: Forecast sales for Pfizer’s Eastern European cancer portfolio, 2004–10 163

Table 4.61: Sanofi-Aventis’ marketed Eastern European cancer portfolio, 2004 165

Table 4.62: Sanofi-Aventis’ oncology R&D pipeline, 2005 165

Table 4.63: Forecast sales for Sanofi-Aventis’ Eastern European cancer portfolio, 2004–10 166

Table 4.64: Schering AG’s marketed Eastern European cancer portfolio, 2004 167

Table 4.65: Schering AG’s cancer R&D pipeline, 2005 168

Table 4.66: Forecast sales for Schering AG’s Eastern European cancer portfolio, 2004–10 169